Cardinal Health vs Cencora
Cencora is the larger business, with $321.33bn of revenue in fiscal 2025 against $254.25bn for Cardinal Health (1.3 times as much). Cardinal Health grew faster (14.2% against 9.3%). Cardinal Health kept more of each dollar of sales as profit: a net margin of 0.7% against 0.5%.
| Latest fiscal year | Cardinal HealthCAH, 2026 | CencoraCOR, 2025 |
|---|---|---|
| Revenue | $254.25bn | $321.33bn |
| Revenue growth | 14.2% | 9.3% |
| Net income | $1.71bn | $1.55bn |
| Operating margin | 1.0% | — |
| Net margin | 0.7% | 0.5% |
| Return on equity | — | 144.3% |
| Free cash flow | $4.53bn | $3.21bn |
| Cash | $4.86bn | $4.36bn |
| Total debt | $8.89bn | $7.66bn |
| Debt to equity | — | — |
| Dividend per share | $2.04 | $2.20 |
| Dividend yield | 0.8% | 0.7% |
| Share buybacks | $1.36bn | $435m |
| Employees | 63,900 | 46,000 |
| Market value | $60.28bn | $64.47bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 40 (Weak) | 40 (Weak) |
| Insider trades, 12 months | 0 buys, 35 sales | 3 buys, 12 sales |